| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Molecular and Clinical Endocrinology and Oncology (A.C., R.P., R.S.A., M.G., G.L.), Section of Endocrinology, and Departments of Neurological Sciences (F.B., F.T.) and Radiology (F.C., S.C.), Section of Neuroradiology, University "Federico II" of Naples, 80131 Naples, Italy
Address all correspondence and requests for reprints to: Annamaria Colao, M.D., Ph.D., Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University of Naples, via S. Pansini 5, 80131 Naples, Italy. E-mail: colao{at}unina.it.
Context: Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly diagnosed patients with acromegaly.
Objective: The objective of the study was to evaluate clinical predictors of tumor shrinkage.
Design: This was an analytical, observational, open, prospective study.
Subjects: The study included 99 patients: 13 with microadenoma and 86 with macroadenoma (25 enclosed, 32 extrasellar, 29 invasive).
Main Outcome Measures: Age, gender, estimated disease duration, body mass index, GH and IGF-I levels, and tumor volume at diagnosis and after 12 months of treatment were measured. Percentage of GH, IGF-I, and tumor size changes from baseline were also analyzed. Tumor changes were scored as absent (± 0–25%), mild (± 25.1–50%), moderate (± 50.1–75%), or notable (75%).
Interventions: Sixty patients (60.6%) received depot octreotide im (20–30 mg every 28 d), and 39 patients (39.4%) received lanreotide im (60–90 mg every 28 d).
Results: Basal tumor volume and maximal tumor diameter correlated with age, disease duration, and GH levels. After 12 months, GH levels were controlled (
2.5 µg/liter) in 57.6%, IGF-I levels in 45.5%, and both in 42.4%. Shrinkage was absent in 22 patients (22.2%), mild in 31 (31.1%), moderate in 30 (30.3%), and notable in 14 patients (14.1%). Two patients (not responding to treatment) had a mild tumor increase (by 34 and 31.2%, respectively). Basal and posttreatment tumor volumes were highly correlated (r = 0.79, P < 0.0001). At the multistep regression analysis, the percent IGF-I decrease (t = 2.6; P = 0.011) was the best predictor of posttreatment tumor volume, followed by patients’ age (t = 2.1; P = 0.042) and percent GH decrease (t = 2.0; P = 0.044).
Conclusions: Most patients with acromegaly (75.5%) had 25% or greater tumor shrinkage after 12 months of primary somatostatin analog therapy: significant increase of tumor mass occurred in only 2.1% of patients (uncontrolled during treatment). Best predictor of tumor shrinkage was posttreatment IGF-I.
This article has been cited by other articles:
 |
|
 |
|
  A. Colao, R. S. Auriemma, M. Galdiero, G. Lombardi, and R. Pivonello Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3746 - 3756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, R. S. Auriemma, S. Savastano, M. Galdiero, L. F. S. Grasso, G. Lombardi, and R. Pivonello Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2907 - 2914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Buchfelder, D Weigel, M Droste, K Mann, B Saller, K Brubach, G K Stalla, M Bidlingmaier, C J Strasburger, and on behalf of the investigators of the German Pegvi Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study Eur. J. Endocrinol., July 1, 2009; 161(1): 27 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Melmed, A. Colao, A. Barkan, M. Molitch, A. B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, et al. Guidelines for Acromegaly Management: An Update J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1509 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, R. S. Auriemma, M. Galdiero, P. Cappabianca, L. M. Cavallo, F. Esposito, L. F. S. Grasso, G. Lombardi, and R. Pivonello Impact of Somatostatin Analogs Versus Surgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 528 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanimoto, N. Hizuka, I. Fukuda, K. Takano, and T. Hanafusa The influence of age on the GH-IGF1 axis in patients with acromegaly Eur. J. Endocrinol., October 1, 2008; 159(4): 375 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, R. Pivonello, R. S. Auriemma, M. Galdiero, S. Savastano, L. F. S. Grasso, and G. Lombardi Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3436 - 3442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Melmed Update in Pituitary Disease J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colao, R. Pivonello, R. S Auriemma, M. Galdiero, S. Savastano, and G. Lombardi Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly Eur. J. Endocrinol., November 1, 2007; 157(5): 579 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bex, R. Abs, G. T'Sjoen, J. Mockel, B. Velkeniers, K. Muermans, and D. Maiter AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects Eur. J. Endocrinol., October 1, 2007; 157(4): 399 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Melmed Acromegaly N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
